Gracellbio
Suzhou, CN · 9 known investors
Find your way into Gracellbio
177 people in our graph share verified history with the Gracellbio team — schools, employers, funds. One of them is your warm intro.
David Mollerunlockedknows Wei (William) Cao · together at Harvard Medical School (overlapped)
×11knows the team · via Stanford University School of Medicine
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases. The company operates manufacturing facilities in China and was acquired by AstraZeneca in February 2024.
Founders & leadership
WW
William Wei CaoinExecutive Officer, Director at Cellular Biomedicine Group
Investors · 9
LAV✓ verifiedHong Kong · $5M – $15M
Lilly Asia Ventures✓ verifiedHong Kongvia Hongbo Lu · inferred
OrbiMed✓ verifiedNew York · $1M – $75M
Exome Asset Management✓ verifiedNew York
Janus Henderson Investors✓ verifiedNew York
Pivotal Life Sciences✓ verifiedSan Francisco
RA Capital✓ verifiedBoston
Temasek✓ verifiedSingapore
Vivo Capital✓ verifiedPalo Alto · $10M – $50M
Frequently asked questions
- What does Gracellbio do?
- Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases. The company operates manufacturing facilities in China and was acquired by AstraZeneca in February 2024.
- Who founded Gracellbio?
- Gracellbio was founded by William Wei Cao.
- Who are Gracellbio's investors?
- Gracellbio's investors include LAV, Lilly Asia Ventures, OrbiMed, Exome Asset Management, Janus Henderson Investors, Pivotal Life Sciences, RA Capital, Temasek and 1 more.
- Where is Gracellbio headquartered?
- Gracellbio is headquartered in Suzhou, CN.